0 Ask Beta Account

Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

K Miyagawa, Josef Rösch, Frank Z Stanczyk, K Hermsmeyer

  • Oregon Health & Science University ROR
  • University of Southern California ROR
  • Oregon National Primate Research Center ROR

Nature Medicine, 3(3), 324-327

DOI 10.1038/nm0397-324 PMID 9055861

Abstract

Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17 beta in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

Topics

Reproductive Endocrinology > Progesterone > Cardiovascular ProtectionPerimenopause/Menopause > Hormone Therapy > Progestin ComparisonContraception/Comparison > Synthetic vs Natural Progesterone > Cardiovascular Effects
medroxyprogesterone versus progesterone coronary vasospasm, Miyagawa Hermsmeyer medroxyprogesterone coronary artery vasospasm, progesterone cardiovascular protection postmenopausal hormone replacement, medroxyprogesterone acetate interferes estradiol coronary protection, ovarian steroid hormones coronary vasospasm rhesus monkey, natural progesterone versus synthetic progestin cardiovascular effects, hormone replacement therapy progestin coronary artery vasospasm risk, estradiol progesterone combination cardiovascular protection ovariectomized primates, MPA versus progesterone heart disease postmenopausal women, medroxyprogesterone acetate cardiovascular risk hormone replacement therapy
PMID 9055861 9055861 DOI 10.1038/nm0397-324 10.1038/nm0397-324

Cite this article

Miyagawa, K., Rösch, J., Stanczyk, F., & Hermsmeyer, K. (1997). Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. *Nature medicine*, *3*(3), 324-327. https://doi.org/10.1038/nm0397-324

Keywords

Animals, Coronary Vasospasm/prevention & Control, Drug Therapy, Combination, Estradiol/administration & Dosage, Estrogen Replacement Therapy, Female, Macaca Mulatta, Medroxyprogesterone/administration & Dosage, Ovariectomy, Progesterone/administration & Dosage, Progesterone Congeners/administration & Dosage, Risk Factors, Progesterone Congeners, Progesterone, Estradiol, Medroxyprogesterone

Related articles

Preserved forearm endothelial responses with acute exposure to progesterone: A randomized cross-over trial of 17-beta estradiol, progesterone, and 17-beta estradiol with progesterone in healthy menopausal women
Mather KJ et al., 2001 The Journal of Clinical Endocrinology and Metabolism

Regularly menstruating women are relatively protected from cardiovascular disease. Epidemiological and endothelial function studies attribute this protection to estradiol (E(2)), but both progesterone...

Perimenopause/Menopause > Hormone Therapy > Progesterone Vascular EffectsReproductive Endocrinology > Progesterone > Cardiovascular ProtectionResearch Methodology > Randomized Crossover Trials > Hormone Infusion Studies

Vaginal microbiome transplantation in women with intractable bacterial vaginosis
Lev-Sagie A et al., 2019 Nature Medicine

We report the results of a first exploratory study testing the use of vaginal microbiome transplantation (VMT) from healthy donors as a therapeutic alternative for patients suffering from symptomatic,...

General OB/GYN > Vaginal Health > Bacterial VaginosisGeneral OB/GYN > Vaginal Health > Microbiome TherapeuticsResearch Methodology > Study Design > Case Series

Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood
Tata B et al., 2018 Nature Medicine

Polycystic ovary syndrome (PCOS) is the main cause of female infertility worldwide and corresponds with a high degree of comorbidities and economic burden. How PCOS is passed on from one generation to...

PCOS > Pathogenesis > Prenatal AMH Fetal ProgrammingReproductive Endocrinology > Developmental Origins > In Utero Hormonal ExposureResearch Methodology > Animal Model > Transgenerational PCOS Transmission

A placental clock controlling the length of human pregnancy
McLean M et al., 1995 Nature Medicine

We report the existence of a 'placental clock', which is active from an early stage in human pregnancy and determines the length of gestation and the timing of parturition and delivery. Using a prospe...

Pregnancy > Parturition > Placental CRH MechanismPregnancy > Preterm Delivery > Early Biomarker PredictionReproductive Endocrinology > Placental Hormones > Corticotropin-Releasing Hormone